upadacitinib
abbvie
['upadacitinib', 'crohn', 'ibd']
panes - upadacitinib 50% clinical remission rates, 45% endoscopic improvement and 29% endo remission at 12 weeks in #crohnsdisease, more than half bio-failures. all signif superior to pbo. response seen as early as 2 weeks. acceptable safety signal #uegweek22 #ibd
Swedish physician specializing in the treatment of Crohn's disease and Ulcerative Colitis. Views - my own.